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Streptococcus pneumoniae is a major cause of
bacterial pneumonia and meningitis in the
United States. The spread of penicillin-
nonsusceptible S. pneumoniae (PNSP) has been
well documented (1-8). Within a large city,
resistance patterns can vary by region (5,8).
Oklahoma City has historically had a relatively
high but stable prevalence of PNSP among
invasive isolates; penicillin nonsusceptibility
was reported in 12.2% of invasive isolates during
1984 (9). From July 1989 through June 1990,
7.6% of invasive isolates from central Oklahoma
were penicillin nonsusceptible, but high penicillin
resistance (1.4%) was beginning to emerge (10).
In late 1997, higher than expected levels of PNSP
were reported in northwest Oklahoma City at
Hospital A, a 392-bed community hospital,
primarily providing adult care. The hospital’s
inpatient census and the proportion of patients
receiving Medicare had not increased since 1994;
however, the microbiology laboratory had
recently begun using the antimicrobial gradient
strip method for measuring antibiotic
susceptibility to penicillin and cephalosporins.
Nonsusceptibility to penicillin among
pneumococcal isolates exceeded 60%;
approximately half were highly penicillin
resistant. We initiated an investigation to
determine whether the reported prevalence was
accurate and if so, to explain it, determine a
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During 1997, Oklahoma City’s Hospital A reported penicillin-nonsusceptible
Streptococcus pneumoniae in almost 67% of isolates. To confirm this finding, all
Hospital A S. pneumoniae isolates from October 23, 1997, through February 19, 1998,
were tested for antibiotic susceptibility and repeat-tested at two other hospital
laboratories. Medical records of Hospital A patients with invasive S. pneumoniae
infections during  1994 through 1997 were also reviewed. These data were compared
with 1998 statewide sentinel hospital surveillance data for invasive S. pneumoniae. Of
48 S. pneumoniae isolates from Hospital A during October 23, 1997, through February
19, 1998, 31 (65%) were penicillin-nonsusceptible S. pneumoniae, and 23 (48%) were
highly penicillin resistant. Similar prevalences were confirmed at the other hospital
laboratories; however, significant interlaboratory differences were noted in the
determination of third-generation cephalosporin susceptibility. During 1994 through
1997, a trend toward increasing penicillin nonsusceptibility (p <0.05) was noted among
S. pneumoniae isolates from nursing home patients. During 1998, 85 (30%) of 282
invasive isolates reported to the state surveillance system were penicillin-
nonsusceptible  S. pneumoniae; 33 (12%) were highly resistant. The increase in
resistance observed is notable; the interlaboratory discrepancies are unexplained. To
respond, a vaccination program was implemented at Hospital A, and vaccination efforts
were initiated at nursing homes.Resear Resear Resear Resear Research ch ch ch ch
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possible trend, and compare the prevalence with
that of local hospitals. Findings were used to
guide local treatment and prevention measures.
The Study
 Prospective Laboratory Survey
To confirm the accuracy of the preliminary
antibiotic susceptibility results from Hospital A,
we prospectively collected all S. pneumoniae
isolates identified by Hospital A’s microbiology
laboratory from October 23, 1997, through
February 19, 1998. An invasive isolate was
defined as any positive culture for S. pneumoniae
obtained from blood; cerebrospinal fluid; joint,
pleural, or peritoneal fluid; or other normally
sterile site. We confirmed the antibiotic
susceptibility profiles of each of these isolates by
retesting them at another community facility,
Hospital B. To determine antibiotic susceptibil-
ity, both hospitals used oxacillin disk screening
followed by the antimicrobial gradient disk
(E-test). The penicillin susceptibility of the
invasive isolates was also confirmed using broth
dilution at the laboratory of Children’s Hospital
of Oklahoma, which serves as the regional
pediatric referral hospital in Oklahoma.
For this report, the term penicillin
nonsusceptible (PNSP)is used to describe any
S. pneumoniae organism with reduced suscepti-
bility to penicillin. We used the National
Committee for Clinical Laboratory Standards’
cut points to identify antibiotic susceptibility and
determine whether nonsusceptible organisms
had intermediate or high resistance (for
penicillin,  < 0.06 µg/mL was considered
susceptible; 0.10-1.00 µg/mL was intermediate,
and  > 2.00 µg/mL was resistant) (11).
Hospitals A and B used the E-test to evaluate
the susceptibility of each isolate to third-
generation cephalosporins, but Hospital A used
cefotaxime as the test antibiotic whereas
Hospital B used ceftriaxone. Both hospitals also
tested isolates for susceptibility to trimethoprim
sulfamethoxazole (TMP-S).
The serotypes of 16 of the S. pneumoniae
isolates (the first 13 invasive isolates collected
and 3 additional noninvasive isolates) from
Hospital A were determined by the Division of
Bacterial and Mycotic Diseases Laboratory,
Centers for Disease Control and Prevention
(CDC). The susceptibility profiles and serotypes
of these isolates were compared with those
obtained from a 1996 nursing home outbreak of
invasive multidrug-resistant S. pneumoniae in a
geographically distant region of Oklahoma (12).
Hospital A Retrospective Cohort Study
To describe the epidemiology of S. pneumoniae
at Hospital A during 1994 through 1997, we
retrospectively identified all patients with
invasive isolates by reviewing records of the
hospital’s microbiology laboratory. After linking
these with patient medical records, we extracted
information on  demographics, medical history,
clinical course, and results of antibiotic suscepti-
bility testing of the isolates for each patient.
Trends over time were determined by the chi-
square for trend test, and potential predictor
factors for acquiring nonsusceptible organisms—
such as hospitalization within the past year at
Hospital A, nursing home residence, and various
demographic factors—were evaluated (Epi-Info
version 6.04b, CDC).
1998 Oklahoma Sentinel Hospital Surveillance
During this investigation, a sentinel hospital
surveillance system was started for invasive S.
pneumoniae in Oklahoma. We compared the
prevalence of PNSP at Hospital A with data from
the 26 sentinel hospitals that participated in this
surveillance system in 1998. Ten were among the
acute-care hospitals studied in central Oklahoma
during 1989 to 1990 (10); the others were
scattered throughout the state. Some hospitals
used bacterial broth dilution or antimicrobial
gradient strips for penicillin susceptibility
testing; others used bacterial disk diffusion or an
antimicrobial panel. The sentinel hospitals
accounted for approximately 58% of all medical
and surgical hospital beds in the state.
Results
Prospective Laboratory Survey
From October 23, 1997, through February 19,
1998, Hospital A’s microbiology laboratory
identified  S. pneumoniae isolates from 48
patients. Of these, 17 (35%) were invasive: 2 were
from cerebrospinal fluid, and 15 were from blood.
The remaining 31 (65%) were noninvasive;  22
isolates were from sputum and 9 from nose,
sinus, tonsils, or bronchial washings. The median
patient age was 60 years; only 5 (10%) were <18
years of age. Of patients, 26 (54%) were male.
Twenty (80%) of the 25 for whom race was knownResear Resear Resear Resear Research ch ch ch ch
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Table 1. Antibiotic-susceptibility test resultsa for 48
isolates of Streptococcus pneumoniae from Hospital A,
Oklahoma, October 23, 1997, through February 19,
1998, and retest results from Hospital B
Hospital A Hospital B
   No. (%)    No. (%)
Oxacillin disk
Sensitive 16/47 (34) 17/46 (37)
Resistant 31/47 (66) 29/46 (63)
Penicillin
Sensitive 17/48 (35) 18/48 (38)
Intermediate  8/48 (17) 16/48 (33)
Resistant 23/48 (48) 14/48 (29)
Ceftriaxone
Sensitive not performed 37/48 (77)
Intermediate  7/48 (15)
Resistant  4/48 (8)
Cefotaxime
Sensitive 25/48 (52) not performed
Intermediate 10/48 (21)
Resistant 13/48 (27)
Trimethoprim-
  sulfamethoxazole
Sensitive 18/47 (38) 16/47 (34)
Intermediate  6/47 (13)   2/47 (4)
Resistant 23/47 (49) 29/47 (62)
aBy E-test and oxacillin disc.
Table 2. Penicillin-susceptibility test results from three
laboratories for 17 invasive isolates of Streptococcus
pneumoniae, Hospital A, Oklahoma, November 1997
through February 1998
E-test Broth dilution
Hospital Hospital  Children’s Hos-
Source A B pital of Oklahoma
Blood I S S
Blood R I R
Blood R R R
Blood R I I
Blood S S S
Blood I I I
Blood R R I
Blood S S S
Blood R I I
Blood S S S
CSF S S S
Blood S S S
Blood I I I
CSF R R I
Blood R R R
Blood R R R
Blood S S S
I or R % 65% 59% 59%
I, having intermediate resistance; R, highly resistant; S,
susceptible to the antibiotic.
CSF = cerebrospinal fluid
were white, 4 (16%) were black, and l (4%) was
Asian. Twenty-nine (60%) of the patients resided
in Oklahoma County; the rest were from seven
other Oklahoma counties. The isolates were
tested at hospitals A and B for susceptibility to
several different antibiotics.
Hospital A reported that 31 (65%) of the 48 S.
pneumoniae isolates were not susceptible to
penicillin; 8 (17%)had intermediate resistance
and 23 (48%) had high penicillin resistance.
Twenty-three (48%) isolates were nonsusceptible
to cefotaxime, and 13 (27%) were highly
cefotaxime resistant. Of 47 isolates tested, 29
(62%) were nonsusceptible to TMP-S; 23 (49%)
were highly resistant (Table 1). All isolates were
susceptible to vancomycin.
When these isolates were tested for penicillin
susceptibility at Hospital B, a similar prevalence
of PNSP was reported (62%), though fewer were
highly resistant (29%). However, when testing
for susceptibility to a third-generation cepha-
losporin was performed at Hospital B, only 11
(23%) of 48 isolates were reported as
nonsusceptible to ceftriaxone, compared with the
23 (48%) nonsusceptible to cefotaxime at
Hospital B (Table 1). For all 15 isolates for which
cefotaxime susceptibility results at Hospital A
differed from ceftriaxone susceptibility results at
Hospital B, the difference was in the direction of
higher resistance to cefotaxime than to ceftriaxone
(sign test, p <0.001).
When penicillin susceptibilities of the 17
invasive isolates tested with the E-test by both
hospitals were compared with the susceptibilities
determined at Children’s Hospital of Oklahoma
using broth dilution, the results were again
similar. For 11 (65%) of the invasive isolates, all
three test results were interpreted as the same.
When discordance was noted, the differences
were minor (i.e., susceptible was interpreted as
intermediate [or vice versa], or intermediate was
interpreted as resistant [or vice versa]).  No
major differences occurred in interpretation of
penicillin susceptibility (susceptible to resistant
or resistant to susceptible) (Table 2).
Among the 16 serotyped isolates, 10
serotypes were identified: 4, 6A, 9V (3 isolates),
12F, 18C, 19A (2 isolates), 22F, 23F (4 isolates),
33F, and 35B. Only two (12.5%)(6A and 35B)
would not have been covered by pneumococcal
vaccine. Among the 23F isolates, two were
invasive, and two were not. One of the invasiveResear Resear Resear Resear Research ch ch ch ch
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23F isolates was highly sensitive to everything
tested; the other three were highly resistant to
several antibiotics and had similar susceptibility
profiles to the 23F isolates identified in the
nursing home outbreak months earlier (12).
Hospital A Retrospective Cohort Study
Review of the epidemiology of S. pneumoniae
infection at Hospital A during 1994 through 1997
revealed 71 case-patients with invasive infec-
tions. Forty-three (61%) were female, 62 (87%)
were white, and 7 (10%) were black. The median
age was 64 (range: 1 to 94), and 21 (30%) patients
died. Twenty-three (32%) had been hospitalized
at Hospital A during the previous 6 months.
Nineteen (27%) were residents of a nursing
home, 51 (72%) acquired infection in the
community, and one (1%) acquired infection
while hospitalized for another illness. Five (7%)
had asplenia. Sixty-five (92%) isolates were from
blood; four (6%) from the joint,  pleural, or
peritoneal fluid; and one (1%) each from
cerebrospinal fluid and an aortic graft. Fifty-six
(79%) infected patients resided in Oklahoma City
or its vicinity.
Fifty-eight (82%) patients with invasive
S. pneumoniae infections during this period fit
the Advisory Committee on Immunization
Practices’ (ACIP) criteria for pneumococcal
vaccine (13). Of the 21 deaths, 20 (95%) would
have met the criteria. Only one patient’s record,
however, showed receipt of pneumococcal
vaccine. This patient had had a splenectomy and
did not survive the infection.
For the 71 case-patients, 27 (38%) isolates
were PNSP, and 13 (18%) were highly resistant.
Fifteen (21%) were nonsusceptible to cefotaxime,
and one (1%) was highly resistant. All isolates
tested were sensitive to vancomycin and
clindamycin. Forty-two (59%) patients with
invasive pneumococcal disease initially received
ceftriaxone, and 3 (4%) received vancomycin; 20
(28%) received vancomycin at some point during
their hospital stay. Case-patients with PNSP
infections were not more likely to die than
patients with penicillin-susceptible infections.
Over the 4-year period of the study, a trend
toward increased nonsusceptibility to penicillin
was noted at Hospital A (1 of 9, 8 of 24, 7 of 20, 11
of 18; p = 0.02). The same trend was noted for
cefotaxime nonsusceptibility (0 of 9, 3 of 24, 5 of
20, 9 of 18; p = 0.008). A significant trend toward
increased penicillin nonsusceptibility was noted
in nursing home patients (0 of 2, 2 of 6, 4 of 7, 4 of
4; p <0.05) but not in non-nursing home residents
(2 of 7, 7 of 18, 4 of 13, 7 of 14; p >0.05).  Nursing
home residents were more likely than non-
nursing home residents to have a nonsusceptible
strain of S. pneumoniae, but this finding was not
significant (10 of 18 vs. 20 of 53, risk ratio [RR] =
1.5; 95% confidence interval [CI] = 0.9 – 2.5;
p > 0.05). Similarly, patients who had been
hospitalized at Hospital A in the previous 6 months
were more likely to have PNSP infections than
those who had not been hospitalized there, but
again the association was not significant (18 of 33
vs. 12 of 38, RR = 1.7; 95% CI = 1.0-3.0; p = 0.09).
1998 Oklahoma Sentinel Surveillance
Surveillance data were available from 26
sentinel hospital laboratories in Oklahoma
during 1998, including Hospital A’s. Seventeen
laboratories used the E-test, four used broth
dilution, three used disk diffusion (Kirby Bauer),
and two used an antimicrobial panel (Microscan)
for susceptibility testing.  Of 282 invasive isolates
tested, 197 (70%) were penicillin susceptible; 52
(18%) had intermediate resistance, and 33 (12%)
were highly penicillin resistant. Of the 26
sentinel hospitals, 13 had at least 10 invasive
isolates of S. pneumoniae during 1998. The
prevalence of PNSP ranged from 10% to 45% in
these 13 hospitals.
Discussion
The high prevalence of PNSP invasive
isolates observed among vaccine-eligible, elderly
adults from Hospital A in Oklahoma City  is
similar to that recently reported as the highest of
a range of proportions from CDC’s Emerging
Infections Program’s Active Bacterial Core
Surveillance for 1997 (8). Penicillin
nonsusceptibility varied among Oklahoma senti-
nel hospitals, but overall it has increased
markedly since studies were conducted in
Oklahoma in the 1980s (9,10).
The increase in penicillin nonsusceptibility
at Hospital A appears to be the result of a trend
over the past 4 years. While we found no evidence
of an increase in the number of patients with
invasive  S. pneumoniae coming from nursing
homes, we did note an increasing prevalence of
PNSP among such patients.
The community in which Hospital A is
located is fairly affluent. Resistance levels can
vary within a city, and more affluent or suburbanResear Resear Resear Resear Research ch ch ch ch
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communities may have higher rates of antibiotic
resistance among S. pneumoniae isolates (5),
perhaps attributable to more frequent use of
antibiotics. Some resistant isolates were similar
to those detected in a recent nursing home
outbreak involving a single clone of a highly
resistant organism (12). Contribution of an
outbreak clone to the high prevalence  observed
here is possible; however, our evidence suggests
that several resistant serotypes contributed to
the observed increase. Although the reason for
the PNSP increase at Hospital A is  unclear, local
antibiotic prescribing practices and one or more
highly resistant clones circulating in the
community or nursing homes may have been
involved.
This investigation had at least three
limitations. First, the number of invasive isolates
for the retrospective study was small, and
specific risk factors for acquiring PNSP at
Hospital A were not identified. Thus, no single
factor explains the high rates observed. Other
studies have suggested that age (< 6, or > 65),
race, recent antibiotic use, socioeconomic status,
and geographic factors may be associated with
resistance (2,5). Second, because of the small
number of isolates collected prospectively
beginning in October 1997, we could not confirm
or explain the significant difference in third-
generation cephalosporin susceptibility reported
by hospitals A and B.  Although these facilities
used two different test antibiotics (cefotaxime
and ceftriaxone) to determine susceptibility, the
genetic mechanism responsible for cephalosporin
resistance would have been expected to have
made the same organisms equally susceptible to
either antibiotic. If confirmed, this finding is
relevant in clinical settings where cefotaxime is
used to test for susceptibility and ceftriaxone is
used for treatment because S. pneumoniae may
not have equal susceptibility to both antibiotics.
Although we found reliability among the three
laboratories for determining penicillin suscepti-
bility, consistent with reports in the microbiology
literature (14,15), the lack of interlaboratory
reliability in differentiating between high and
intermediate penicillin resistance was also
unexplained. Finally, we did not assess whether
treatment failure contributed to illness and
death. Although case-patients with PNSP
infections were not more likely to die than
patients with penicillin-susceptible infections,
the impact of underlying illnesses and the
virulence of the infecting strain on the outcome is
not known.
For Hospital A and the state of Oklahoma,
our findings have implications for disease
treatment and prevention.  Surveillance, in-
creased use of the pneumococcal vaccine, and
judicious use of antimicrobial drugs are
important components of the effort to limit the
spread of resistant S. pneumoniae (3,13,16).  For
determining community-specific prevalence of
PNSP infections, use of hospital antibiograms
has been shown to be comparable to active
surveillance with centralized testing (17).
However, our investigation suggested that when
different third-generation cephalosporin test
antibiotics are used and when determining high
versus intermediate penicillin nonsusceptibility,
significant differences can occur between hospi-
tal laboratories in the determination of suscepti-
bility. Such differences, whatever their explana-
tion, have important clinical implications for the
optimal use of antibiotics (e.g., vancomycin,
ceftriaxone, and fluoroquinolones). Accurate
laboratory information is needed at the local level
to optimize use of antibiotics and minimize the
development of antibiotic resistance. Accurate
surveillance information is needed at the state
level to compare regional prevalences. Further
study with more isolates is needed to identify
ways to improve the accuracy of this surveillance
system.
This investigation documented that many
cases of invasive pneumococcal disease could
have been prevented by improved immunization
practices: 82% of Hospital A case-patients during
1994 to 1997 were eligible for vaccine by ACIP
criteria, but only one had record of receiving it.
Although hospital records may not have reflected
true vaccination status, 1997 data from the
Behavioral Risk Factor Surveillance System
showed that 40% of Oklahoma residents > 65
reported having received the pneumonia vaccine,
which is less than the national goal of >60% (18).
Targeting vaccination programs at nursing
homes may be particularly effective. Oklahoma
has recently required that all nursing homes
offer pneumococcal vaccination to their residents
and provide documentation of vaccination status.
In addition, Hospital A instituted a hospital-
based pneumococcal immunization program with
standing orders to vaccinate inpatients aged  65
years who are eligible for the vaccine based on
ACIP criteria (13). Because nearly one out ofResear Resear Resear Resear Research ch ch ch ch
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three of the patients with invasive pneumococcal
disease admitted to Hospital A during 1994 to
1997 had been hospitalized there in the previous
6 months, an inpatient screening and vaccination
program could have prevented a substantial
number of cases. Hospital-based programs have
been shown to be effective in vaccinating high-
risk adults in other settings (19-21), and the use
of standing orders to vaccinate eligible adults
with pneumococcal vaccine has been recom-
mended by the Task Force on Community
Preventive Services (22). Adult vaccination
programs in nontraditional settings (e.g., pharma-
cies, churches, and the workplace) might further
raise vaccination coverage in this area (23).
Finally, efforts to promote judicious use of
antibiotics are needed to minimize the spread of
antibiotic-resistant  S.  pneumoniae. Several
studies have demonstrated that antimicrobial
drug use is associated with resistance in S.
pneumoniae (24-26). A combination of interven-
tions involving education of both physicians and
patients has been successful in reducing
antibiotic use (27) and would likely reduce the
trend of increasing resistance in Oklahoma.
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